Date of first investment: 2023
About Deciphex
Deciphex is at the forefront of digital pathology and AI, providing innovative solutions that drive efficiencies in pathology research and diagnostics. Through technological excellence and a commitment to innovation, Deciphex aims to transform the industry, enhancing healthcare outcomes across the globe.
Claret first invested in Deciphex, a CEGCF III portfolio company, in 2023, supporting the company’s mission as it continues to transform pathology through digital innovation.
The investment is being used to fuel Deciphex’s growth capacity, headcount increase, service enhancement, and expansion into new markets, addressing the growing global demand in pathology services.
“Since Claret has become involved with Deciphex, we’ve scaled our reach in international markets, we’ve grown our commercial organisations, we’ve grown in scale revenue. We’ve had the ability to do that through access to capital.” – Donal O’Shea, CEO of Deciphex.